Corcept Therapeutics (CORT) Liabilities and Shareholders Equity (2010 - 2026)

Corcept Therapeutics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $888.7 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 10.85% year-over-year to $888.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.4 billion (up 2.78% YoY) and the FY2025 annual result came in at $836.7 million, changed 0.46% from the prior year.
• Liabilities and Shareholders Equity climbed to $888.7 million in Q2 2026 per CORT's latest filing, from $814.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $888.7 million in Q2 2026 and troughed at $468.1 million in Q1 2022.
• A 5-year average of $691.5 million and a median of $685.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 37.68% in 2022, down 15.26% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $583.4 million in 2022, then grew by 6.53% to $621.5 million in 2023, then jumped by 35.24% to $840.6 million in 2024, then dropped by 0.46% to $836.7 million in 2025, then advanced by 6.22% to $888.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $888.7 million, $814.9 million, and $836.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.